Intech Biopharm

Intech Biopharm Days Payable Outstanding

The Days Payable Outstanding (DPO) of Intech Biopharm (6461.TWO) as of Oct 30, 2026 is 6.51. In the previous year, Days Payable Outstanding (DPO) was 18.16 — a change of -64.15% (lower).

Days Payable Outstanding

6.51

YoY

-64.15%

Last updated:

Days Payable Outstanding (DPO) of Intech Biopharm is 2025 6.51 . Days Payable Outstanding (DPO) of Intech Biopharm was 2024 18.16 . It decreases by -64.15% lower compared to the previous year.

The Intech Biopharm Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2018
106.61 TWD
Jan 1, 2019
0.87 TWD
Jan 1, 2020
2.32 TWD
Jan 1, 2021
5.54 TWD
Jan 1, 2022
2.83 TWD
Jan 1, 2023
0.59 TWD
Jan 1, 2024
18.16 TWD
Jan 1, 2025
6.51 TWD
The Intech Biopharm Days Payable Outstanding history
YEARDays Payable OutstandingYoY
6.51-64.15%
18.16+2,956.56%
0.59-79.01%
2.83-48.92%
5.54+139.24%
2.32+165.34%
0.87-99.18%
106.61—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Intech Biopharm Stock analysis

What does Intech Biopharm do? Intech Biopharm Ltd is a pharmaceutical company based in Taipei City, Taiwan. The company went public on July 15, 2014, with the ticker symbol 6461.TWO and ISIN TW0006461007. It operates within the Health Care sector, specifically in the Pharmaceuticals industry. Intech Biopharm focuses on developing drugs for obstructive airway diseases, including bronchial asthma and chronic obstructive pulmonary disease. The company's primary products are respiratory drugs, notably the Duasma hexafluoroacetone (HFA) metered-dose inhalers (MDIs) and the Synvent HFA MDIs. These products are distributed both domestically within Taiwan and internationally. The company maintains a website at http://www.intechbiopharm.com/ for further information. Intech Biopharm Ltd is engaged in the research, development, and distribution of pharmaceutical products targeting respiratory conditions, with a focus on innovative inhaler technologies. The firm's operations are centered on addressing unmet medical needs in respiratory care through its specialized drug formulations. Intech Biopharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Intech Biopharm stock

Days Payable Outstanding (DPO) of Intech Biopharm is 6.51 in 2025.

Days Payable Outstanding (DPO) of Intech Biopharm changed from 18.16 to 6.51, representing a -64.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) Intech Biopharm since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s Intech Biopharm with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Intech Biopharm

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Intech Biopharm